View Document Preview and Link Document Date: 2005-08-08 12:20:59 Open Document File Size: 96,27 KB Share Result on Facebook
Company GlaxoSmithKline / / Country United States / / Event FDA Phase / / IndustryTerm prevention of malaria / Malaria Treatment / Treatment of malaria / / MedicalCondition fever / Stevens-Johnson syndrome / falciparum malaria / abdominal pain / vomiting / urticaria / erythema multiforme / headache / seizures / malaria / diarrhea / P. falciparum malaria / Cough / hallucinations / rash / pruritis / acute P. falciparum malaria / acute uncomplicated P. falciparum malaria / / Organization Pediatric Drug Development Center for Drug Evaluation / Atovaquone-Proguanil Pediatric Advisory Committee / Food and Drug Administration / FAAP Medical Officer Division / / Person Alan M. Shapiro / / Product Malarone Pediatric / Dispensed prescriptions / Malarone / Indication / / Technology Drug Development / / SocialTag 
One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005